Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Using chitosan core-shell nanoparticle for breast cancer treatment

Abstract:
Researchers at National Nanotechnology Center (NANOTEC) and King Mongkut's University of Technology Thonburi (KMUTT) have successfully developed a target drug delivery system using folate-conjugated pluronic F127/chitosan core-shell nanoparticles to deliver doxorubicin (DOX) to target cancer cells focusing on breast cancer.

Using chitosan core-shell nanoparticle for breast cancer treatment

Pathumthani, Thailand | Posted on May 31st, 2012

"DOX is one of the most commonly used chemotherapeutic agents for cancer treatment including breast cancer. However, DOX is also considered a poor soluble drug that is toxic to healthy tissues" said Dr. Nuttaporn Pimpha, a NANOTEC researcher at Hybrid Nanostructure and Nanocomposite. "By using core-shell nanoparticles from folate-conjugated pluronic F127/chitosan we were able to develop a delivery vector that has greater targeting ability, chemical stability and lower cytotoxicity".

As in many developing countries, cancer in Thailand is becoming a significant health problem. Cervix and breast cancer is the leading cause of death in Thai women. The only commercial DOX - encapsulated liposome available is Doxil. However, Doxil has a short half-life in microcirculation and is unstable in the blood stream. Hence there is a need to find a more controlled and stable DOX carrier system.

The researchers reported their work in a paper published by the Journal of Nanomaterials.

####

For more information, please click here

Contacts:
Ramjitti Indaraprasirt
Manager
Public Relations Section
NANOTEC
02-564-7100 ext: 6617

Copyright © NANOTEC

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease February 22nd, 2018

MEMS chips get metatlenses: Combining metasurface lenses with MEMS technology could add high-speed scanning and enhance focusing capability of optical systems February 21st, 2018

Atomic structure of ultrasound material not what anyone expected February 21st, 2018

Oxford Instruments announces Dr Kate Ross as winner of the 2018 Lee Osheroff Richardson Science Prize for North and South America February 20th, 2018

Nanomedicine

Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease February 22nd, 2018

Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B February 15th, 2018

Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT February 15th, 2018

'Living bandages': NUST MISIS scientists develop biocompatible anti-burn nanofibers February 15th, 2018

Announcements

Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease February 22nd, 2018

MEMS chips get metatlenses: Combining metasurface lenses with MEMS technology could add high-speed scanning and enhance focusing capability of optical systems February 21st, 2018

Atomic structure of ultrasound material not what anyone expected February 21st, 2018

Oxford Instruments announces Dr Kate Ross as winner of the 2018 Lee Osheroff Richardson Science Prize for North and South America February 20th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project